Latest / Bloomberg Intelligence / AI Chipmaker Cerebras Systems Seeks $4.8 Billion in Upsized IPO

Transcript

AI Chipmaker Cerebras Systems Seeks $4.8 Billion in Upsized IPO · Bloomberg Intelligence

• 0:02
  Speaker 1: Bloomberg Audio Studios, podcasts, radio news. You're listening to the
• 0:10
  Speaker 1: Bloomberg Intelligence Podcast. Catch us live weekdays at ten am
• 0:14
  Speaker 1: Eastern on Apple, Cocklay and Android Auto with the Bloomberg
• 0:17
  Speaker 1: Business App. Listen on demand wherever you get your podcasts,
• 0:21
  Speaker 1: or watch us live on YouTube.
• 0:24
  Speaker 2: Bloomberg's Carmen Ryankey. Carmen is going to stay with us
• 0:27
  Speaker 2: because she wrote a very cool story on yet another
• 0:31
  Speaker 2: monster IPO that is you guessed it over subscribed. Carmen
• 0:35
  Speaker 2: talked to us about which deal you're looking at you.
• 0:38
  Speaker 3: Yeah, so we're looking at Sarah Bross Systems. So the
• 0:41
  Speaker 3: thing that's interesting here, So it's an artificial artificial intelligence
• 0:44
  Speaker 3: chip maker, data center operator. Obviously all the age right now,
• 0:47
  Speaker 3: we're seeing so much demand for these kinds of companies.
• 0:51
  Speaker 3: The company has upsized its initial public offering, so it's
• 0:56
  Speaker 3: now looking to raise nearly five billion. This is a
• 1:00
  Speaker 3: few so we had reported previously there was they had,
• 1:04
  Speaker 3: you know, a different price that they were seeking. And
• 1:06
  Speaker 3: this company also had applied for an IPO a few
• 1:11
  Speaker 3: months ago and with drawn nellisting and so they're back
• 1:13
  Speaker 3: to the public market here, but yeah, really significant. It's
• 1:17
  Speaker 3: expected to price later this week, so we'll be watching
• 1:20
  Speaker 3: for that day as well as well as the launch
• 1:21
  Speaker 3: of it.
• 1:22
  Speaker 2: Is unusual here, it's just the IPO price itself. Why
• 1:24
  Speaker 2: does it so high? One hundred and thirty five? Initially
• 1:28
  Speaker 2: it was one fifteen oh one twenty five. You don't
• 1:29
  Speaker 2: see that very.
• 1:30
  Speaker 3: Often, I know. Well, now we're seeing one fifty to
• 1:33
  Speaker 3: one sixty each. I mean, I think there's just so
• 1:35
  Speaker 3: much a demand in this category right especially we were
• 1:38
  Speaker 3: in this huge build out. We need data centers. There's
• 1:41
  Speaker 3: a chip shortage, so investors are really like clamoring for
• 1:44
  Speaker 3: more ways to play the AI trade.
• 1:46
  Speaker 4: I guess they don't need to make sure the price
• 1:48
  Speaker 4: is low because of what they do. They're an AI
• 1:50
  Speaker 4: chip maker, So if you want it, you got to
• 1:51
  Speaker 4: pay up.
• 1:52
  Speaker 2: Yeah, But it used to be we can back in
• 1:55
  Speaker 2: the day, you'd want to sell twenty to twenty five
• 1:58
  Speaker 2: percent of the deal to retail. In retail, it's a
• 2:00
  Speaker 2: lot easier to buy a twenty dollars stock or twenty
• 2:02
  Speaker 2: five dollars stock, just intuitively versus this now. But in
• 2:05
  Speaker 2: today's day and age, you can buy fractional shares and
• 2:08
  Speaker 2: that's how that gets done.
• 2:09
  Speaker 5: I guess, so I.
• 2:09
  Speaker 4: Mean, when bitcoins at eighty thousand, you think of that
• 2:12
  Speaker 4: as kind of the dividing line than like an IPO
• 2:14
  Speaker 4: at one hundred and twenty five, one hundred and thirty.
• 2:17
  Speaker 2: Okay, it's partly just gonna be a good I mean well,
• 2:19
  Speaker 2: to be an IPO banker. This year's going to be
• 2:21
  Speaker 2: just ripping, all right. This this deal's been led by Morgan, Stanley,
• 2:24
  Speaker 2: City Group, Barclay's and Ubs, so pretty.
• 2:25
  Speaker 4: Good they're getting paid. Yep, all right, Thank you so much.
• 2:28
  Speaker 4: Carmen Reinikey with the latest on our stock overs as
• 2:31
  Speaker 4: well as this upcoming IPO.
• 2:35
  Speaker 5: Stay with us.
• 2:35
  Speaker 4: More from Bloomberg Intelligence coming up after this.
• 2:41
  Speaker 1: You're listening to the Bloomberg Intelligence podcast. Catch us live
• 2:45
  Speaker 1: weekdays at ten am Eastern on Apple, Cocklay and Android
• 2:48
  Speaker 1: Auto with the Bloomberg Business app. Listen on demand wherever
• 2:51
  Speaker 1: you get your podcasts, or watch us live on YouTube.
• 2:56
  Speaker 2: Scarlett pu and Paul Sweeney live here in our Bloomberg
• 2:58
  Speaker 2: In Directive Broker Studio streaming live on YouTube as well.
• 3:01
  Speaker 5: Well.
• 3:01
  Speaker 2: Joran Powell's term as Federal Reserve Chair ends on May fifteenth.
• 3:05
  Speaker 2: You will, however, remain a member of the Board of
• 3:08
  Speaker 2: governors until January thirty first, twenty twenty eight, much to
• 3:12
  Speaker 2: the Shagrina, President Donald Trump here, and that is a
• 3:15
  Speaker 2: subject of our Big Take story on the Bloomberg terminal today.
• 3:19
  Speaker 2: Katerina Sarajeva, Federal Reserve reporter for Bloomberg News. She joins
• 3:23
  Speaker 2: us from our Houston bureau. Katerina, change is taking place
• 3:27
  Speaker 2: at the Federal Reserve. FED Chairman j Palell stepping down.
• 3:31
  Speaker 2: What is his legacy going to be?
• 3:32
  Speaker 5: You believe? Yeah?
• 3:35
  Speaker 6: I mean it's really interesting, right because he's had a
• 3:38
  Speaker 6: jam packed eight years this chair. We've seen a global
• 3:41
  Speaker 6: pandemic and all that that did to the economy. We
• 3:46
  Speaker 6: saw the run up in inflation after that, and I
• 3:48
  Speaker 6: think in any kind of normal time that that would
• 3:53
  Speaker 6: have been his legacy, his response to the pandemic, but
• 3:57
  Speaker 6: also kind of the FEDS delay in raising rates to
• 4:00
  Speaker 6: combat that high inflation. But now, you know, I think
• 4:04
  Speaker 6: a lot of people are looking to what's currently going
• 4:06
  Speaker 6: on between the FED chair and the presidents as perhaps
• 4:11
  Speaker 6: really marking Chair Powell's legacy, and that's kind of this
• 4:15
  Speaker 6: battle to keep the FED independent.
• 4:19
  Speaker 4: How do you anticipate J. Powell to behave as a
• 4:22
  Speaker 4: FED board member, but not the FED chair, because he's
• 4:26
  Speaker 4: going to stay on in his role as a member
• 4:29
  Speaker 4: of the board even as he hands reins as FED
• 4:32
  Speaker 4: chair over to Kevin.
• 4:33
  Speaker 6: Worsh Yeah, that's right, and it's an unusual step. We've
• 4:37
  Speaker 6: only ever seen this once before in history, and that
• 4:40
  Speaker 6: was in the late forties, early fifties, so it's been
• 4:44
  Speaker 6: a long time. We don't really have a blueprint for this,
• 4:47
  Speaker 6: but what he has said Chair Powell himself is that
• 4:51
  Speaker 6: he will take a very kind of low key approach
• 4:54
  Speaker 6: to this. He won't be, you know, we won't be
• 4:57
  Speaker 6: hearing from him a lot. He won't be trying to
• 5:00
  Speaker 6: act as kind of a shadow chair or anything like that.
• 5:04
  Speaker 6: So it really does seem like he wants to kind
• 5:07
  Speaker 6: of fade into the background a little bit, obviously do
• 5:10
  Speaker 6: his job as a governor, but not be too out
• 5:13
  Speaker 6: in the open about it. Really let the new chair
• 5:16
  Speaker 6: kind of take over.
• 5:18
  Speaker 2: So, Katerina, I'm sure President Trump would like to see
• 5:21
  Speaker 2: Jerome Powell just off the FED all together, but presumably
• 5:25
  Speaker 2: that would take some greater reassurance that mister Powell would
• 5:29
  Speaker 2: not have legal liability in the future. Are we anywhere
• 5:32
  Speaker 2: along those discussions are those discussions even being had.
• 5:36
  Speaker 6: Yeah, I mean, I think you're right about that. And
• 5:38
  Speaker 6: also I think he wants to see some or have
• 5:41
  Speaker 6: some sort of assurance that the FED itself also won't
• 5:44
  Speaker 6: be that there won't be further legal attacks against it.
• 5:49
  Speaker 6: So you know, that would be like the administration trying
• 5:52
  Speaker 6: to fire someone else at the FED. So, I mean,
• 5:55
  Speaker 6: we have a couple things happening right now. There is
• 5:58
  Speaker 6: an internal investigation going on that the FED is now
• 6:02
  Speaker 6: conducting itself into, uh into this the Powell's testimony last
• 6:08
  Speaker 6: year before Congress. This was the reason why we had
• 6:13
  Speaker 6: the the DOJ investigation in the fall and winter, why
• 6:17
  Speaker 6: we had these subpoenas against Powell. This is what started
• 6:20
  Speaker 6: this whole criminal process against him that has been passed
• 6:24
  Speaker 6: along to the FED, so that at some point we'll
• 6:26
  Speaker 6: get a report on that and they can make criminal
• 6:29
  Speaker 6: recommendations to the d J if they see fit. So
• 6:33
  Speaker 6: I think you'll want to see that through. And then
• 6:35
  Speaker 6: we're also waiting on a Supreme Court decision about Governor
• 6:40
  Speaker 6: Lisa Cook, who Trump tried to fire last year, So
• 6:43
  Speaker 6: I think he will also want to kind of see that,
• 6:46
  Speaker 6: I'm guessing. So there's a there's a few different things
• 6:50
  Speaker 6: kind of hanging in the air still.
• 6:52
  Speaker 4: When it comes to Powell's legacy, I think about how
• 6:55
  Speaker 4: Ben Bernanki his predecessor, created this president where there's a
• 7:00
  Speaker 4: news conference after every decision as opposed to after certain decisions.
• 7:05
  Speaker 4: What did j Powell do that kind of changed the
• 7:07
  Speaker 4: way the FED communicates with the public.
• 7:10
  Speaker 6: Yeah, so so Chair Bernanke started the press conferences, but
• 7:14
  Speaker 6: they were just quarterly when he and when then FED
• 7:18
  Speaker 6: Chair Jana Yellen were doing them. Powell actually is the
• 7:21
  Speaker 6: one that started doing them after every meeting.
• 7:23
  Speaker 4: I see, thinks, yeah, which.
• 7:25
  Speaker 6: Is so that that's definitely kind of a communication legacy
• 7:30
  Speaker 6: for him, and we'll see if that continues in the warshare.
• 7:35
  Speaker 2: Yeah, in addition to sitting on the FED board. We
• 7:38
  Speaker 2: as mister Powell said, whether what he will do now
• 7:42
  Speaker 2: he steps down from the FED chairmanship is you can
• 7:44
  Speaker 2: do anything outside of the FED.
• 7:47
  Speaker 6: No, And they usually don't. I mean, that's a full
• 7:49
  Speaker 6: time job. They usually you know, no one at the FED.
• 7:54
  Speaker 6: None of the FED policymakers right now have other jobs
• 7:57
  Speaker 6: or do anything else. That's their their sole focus. So
• 8:02
  Speaker 6: I wouldn't expect that from him and honestly, even if
• 8:05
  Speaker 6: he were to fully leave, or whenever he does fully
• 8:08
  Speaker 6: leave the FED, I don't know if we'll see him
• 8:10
  Speaker 6: do anything else. You know, he's in his seventies, he
• 8:15
  Speaker 6: has grandchildren that he talks about frequently, So I don't
• 8:18
  Speaker 6: know if we would if I would expect him to
• 8:20
  Speaker 6: do a lot, even after he leaves the FED.
• 8:24
  Speaker 4: Sounds like he's ready for retirement, as he stays on
• 8:27
  Speaker 4: the FED board but is no longer chair. Is he
• 8:29
  Speaker 4: going to be a prolific FED speaker? You know, if
• 8:32
  Speaker 4: you go to Eco, go on the Bloomberg terminal, you
• 8:34
  Speaker 4: can see which FED governors or FED officials will be speaking.
• 8:37
  Speaker 4: Do we expect j. Powell to do any of that?
• 8:40
  Speaker 6: I don't think so we're not much That's at least
• 8:43
  Speaker 6: what he's indicated. He said, you know, we won't be
• 8:47
  Speaker 6: hearing from him that much, So I mean I would
• 8:49
  Speaker 6: expect maybe every once in a while a speech, and
• 8:53
  Speaker 6: the governors do speak frequently, as you mentioned, so that
• 8:55
  Speaker 6: is normal for them. But I think because he has
• 8:59
  Speaker 6: you know this this he was or you know, is
• 9:02
  Speaker 6: the chair soon to be stepping down. But because he
• 9:05
  Speaker 6: has that background, I think he'll want to be careful
• 9:09
  Speaker 6: because it might come off as him trying to steer
• 9:12
  Speaker 6: the committee or kind of come back to that leadership role, right,
• 9:16
  Speaker 6: and he definitely does not, you know, has said he
• 9:20
  Speaker 6: doesn't want to be doing that.
• 9:22
  Speaker 1: Kevin D.
• 9:22
  Speaker 2: Walsh joining come into FED chair. What are the expectations
• 9:27
  Speaker 2: now within you know, Fed watchers about what he's going
• 9:31
  Speaker 2: to do in his first days and weeks.
• 9:34
  Speaker 6: Yeah, I mean it's really interesting. He has spent a
• 9:37
  Speaker 6: long time over the past few years. He's really written
• 9:42
  Speaker 6: a lot about what he would like to change at
• 9:44
  Speaker 6: the FED and some of the things he would like
• 9:46
  Speaker 6: to do, everything from how the FED communicates and to
• 9:51
  Speaker 6: how it thinks about inflation, the kind of models it uses,
• 9:56
  Speaker 6: even the FED staff. So he's said a lot of
• 9:59
  Speaker 6: these things. But we just don't know how quickly he's
• 10:02
  Speaker 6: going to be able to implement some of these changes,
• 10:05
  Speaker 6: or how quickly he'll want to. I mean, I imagine
• 10:07
  Speaker 6: that he'll probably want to kind of get a lay
• 10:10
  Speaker 6: of the land. You know, he was a FED governor
• 10:13
  Speaker 6: but fifteen years ago at this point, right, so a
• 10:15
  Speaker 6: long time ago. So I imagine maybe in the first
• 10:19
  Speaker 6: few weeks we won't see a lot of change yet,
• 10:22
  Speaker 6: and then gradually kind of over time, we'll start to
• 10:25
  Speaker 6: see some things change, but we'll just have to see.
• 10:29
  Speaker 6: We really don't know. We haven't gotten a lot of
• 10:31
  Speaker 6: specifics from him about you know, when he'll do the
• 10:35
  Speaker 6: things he wants to do.
• 10:36
  Speaker 4: All right, good stuff, Thank you so much. Katerina Sariva
• 10:39
  Speaker 4: is our Bloomberg News FED reporter joining us from Houston.
• 10:42
  Speaker 4: And I guess that gets to the point Paul, about
• 10:44
  Speaker 4: how the FED is a consensus driven organization institution. Is
• 10:48
  Speaker 4: that by tradition or is that by you know, by rules,
• 10:52
  Speaker 4: like is that kind of written.
• 10:53
  Speaker 5: I don't know.
• 10:54
  Speaker 2: I'm not sure, but I think it's you know, there's
• 10:57
  Speaker 2: oftentimes like to act with be union ANIMs have the
• 11:01
  Speaker 2: unanimous votes. But now we're getting some dissenters, and maybe
• 11:04
  Speaker 2: we'll get more dissenters going forward.
• 11:06
  Speaker 4: Yeah, that's certainly been the case over the last year.
• 11:08
  Speaker 4: The dissension. Something that's normal at the Bank of England
• 11:11
  Speaker 4: less normal right at the FED.
• 11:13
  Speaker 1: Stay with us.
• 11:14
  Speaker 2: More from Bloomberg Intelligence coming up after this.
• 11:20
  Speaker 1: You're listening to the Bloomberg Intelligence podcast. Catch us live
• 11:24
  Speaker 1: weekdays at ten am Eastern on Apple Cocklay and Android
• 11:27
  Speaker 1: Auto with the Bloomberg Business app listen on demand wherever
• 11:31
  Speaker 1: you get your podcasts, or watch us live on YouTube.
• 11:35
  Speaker 4: We want to focus in on what's going on in
• 11:37
  Speaker 4: the pharmer space, and especially you know, with a potential
• 11:41
  Speaker 4: change coming up at the head of the FDA. Sam
• 11:45
  Speaker 4: Vizzelli is our go to guy for all things pharma.
• 11:47
  Speaker 4: He is our director of research for Global Industries and
• 11:49
  Speaker 4: our senior pharmaceuticals analysts joining us right now from London. Sam,
• 11:54
  Speaker 4: the issue at hand is the future of the FDA
• 11:56
  Speaker 4: Commissioner Marty McCarey. There's a lot of tension and I'm
• 12:01
  Speaker 4: not sure if it's because there's clashing with rfk's MAHA
• 12:05
  Speaker 4: priorities or clashing with conservatives over things like the abortion
• 12:09
  Speaker 4: pill access, but there's a lot of unrest in the
• 12:12
  Speaker 4: FDA and the reports are that President Trump will be
• 12:16
  Speaker 4: replacing Martin McCay soon. What is the issue specifically from
• 12:20
  Speaker 4: where you see it?
• 12:22
  Speaker 5: Yeah, so, Scarlett, I mean the FDA since.
• 12:25
  Speaker 7: The change in administration, and they are obviously the appointment
• 12:31
  Speaker 7: of Robert Kennedy Junior to Hhshitch Overseas. Because some of
• 12:34
  Speaker 7: this has been in quite a bit of flux. The
• 12:40
  Speaker 7: Center for Drug Evaluation and Research, see that it takes
• 12:44
  Speaker 7: after drug approvals, looks after drug approvals.
• 12:47
  Speaker 5: That head has changed.
• 12:49
  Speaker 7: The Center for Biologics Evaluation and Research, which takes looks
• 12:52
  Speaker 7: after vaccines and gene therapies, et cetera, got a new head,
• 12:57
  Speaker 7: n A Prasad that had left as five which way
• 13:01
  Speaker 7: he was and then he came backing in and now
• 13:02
  Speaker 7: he's going again.
• 13:03
  Speaker 5: So there's been a lot of flux.
• 13:05
  Speaker 7: And when you get flux and they fired I don't
• 13:06
  Speaker 7: know three thousand, five hundred individuals, maybe I don't have
• 13:10
  Speaker 7: the exact number, but something in that sort of region,
• 13:13
  Speaker 7: you know, that's This is a lot of old time
• 13:15
  Speaker 7: knowledge that's left the agency.
• 13:18
  Speaker 5: Some refresh is pretty good, but that all of this
• 13:22
  Speaker 5: has happened under.
• 13:23
  Speaker 7: The the curre takership of Marty McCarey. And to all
• 13:29
  Speaker 7: instances and purposes, the folks I talk to say that
• 13:32
  Speaker 7: he's a perfectly knowledgeable, wonderful man. I have friends on
• 13:36
  Speaker 7: this on the by side who say to me that
• 13:38
  Speaker 7: he's been very good to them. And then on the
• 13:40
  Speaker 7: other hand, we hear all these issues and some biotics
• 13:43
  Speaker 7: having issues, et cetera. So I wouldn't be surprised if
• 13:47
  Speaker 7: there's something happening here.
• 13:48
  Speaker 4: What has Martin McCay done well? I mean, I think
• 13:51
  Speaker 4: about from a personal point of view, he's made estrogen
• 13:54
  Speaker 4: patches more accessible for women who are suffering through menopause,
• 13:57
  Speaker 4: and that's something he's written about in his book as well.
• 14:00
  Speaker 4: What has he done that, you know, will kind of
• 14:02
  Speaker 4: service his legacy if he does end up leaving.
• 14:06
  Speaker 7: Well, I think what was what's been good is that
• 14:10
  Speaker 7: he's much more available for us to hear from.
• 14:13
  Speaker 5: Do you know what I mean?
• 14:14
  Speaker 7: He does Twitter videos, sit downs and discusses and brings
• 14:19
  Speaker 7: ideas and wants to make animal.
• 14:21
  Speaker 5: Testing less uh required.
• 14:25
  Speaker 7: He wants to get drug development timelines shortened. They've done
• 14:30
  Speaker 7: some deals with air Faster Seneca and one of the
• 14:32
  Speaker 7: former company, Amgen. I think to try and reduce the
• 14:35
  Speaker 7: time of drug development, which gives farmer companies the.
• 14:38
  Speaker 5: Ability to bring drugs faster to patients.
• 14:41
  Speaker 7: What the problem is is that there's been all this
• 14:45
  Speaker 7: upheaval and issues with not knowing exactly what to expect
• 14:49
  Speaker 7: having had a deal with the FDA. When you go
• 14:51
  Speaker 7: back with your data and you know, bring some of
• 14:53
  Speaker 7: these things into public conversation where it shouldn't have been done.
• 14:57
  Speaker 7: So there's pluses and minuses here for and what the
• 15:00
  Speaker 7: FDA now needs is a solid a good, solid pair
• 15:05
  Speaker 7: of hands that just just get gets down to the
• 15:08
  Speaker 7: business of looking at the safety and efficacy of drugs. SAM.
• 15:12
  Speaker 2: If you know, when you talk to your pharma companies
• 15:15
  Speaker 2: and biotech companies, is it harder to get stuff done
• 15:18
  Speaker 2: today under this administration?
• 15:21
  Speaker 5: Easier?
• 15:22
  Speaker 2: About the same? Puts in takes kind of what's the
• 15:24
  Speaker 2: overall view.
• 15:25
  Speaker 5: Yeah, I would say it puts and takes. It's a
• 15:27
  Speaker 5: perfect phrase, yeah, because it depends who you talk to.
• 15:29
  Speaker 5: It depends whether you talk to the main public or
• 15:31
  Speaker 5: in private.
• 15:32
  Speaker 7: If you talk to you know, nobody wants to upset
• 15:35
  Speaker 7: the agency because if you already have some trouble or
• 15:37
  Speaker 7: some problem or some friction, why would you want.
• 15:39
  Speaker 5: To add to it.
• 15:40
  Speaker 7: So if you look at what companies are saying publicly,
• 15:44
  Speaker 7: everything's fine. But then companies go and say, well, you know,
• 15:47
  Speaker 7: we've had this drug discussion with the FDA. This was
• 15:50
  Speaker 7: what we were told to do, we did it, and
• 15:52
  Speaker 7: now they say no. So there's some of that going on,
• 15:55
  Speaker 7: which of course is reality. So I think it all
• 15:58
  Speaker 7: depends on who you talk to when you talk to
• 16:01
  Speaker 7: them in what's setting, you know, I think I think
• 16:04
  Speaker 7: that folks wouldn't mind the change here.
• 16:07
  Speaker 4: Before we you go, Sam, I got to ask you
• 16:08
  Speaker 4: about the hunt of virus that is been a big
• 16:11
  Speaker 4: issue with one of the cruise ships. We know that
• 16:14
  Speaker 4: Gene Hackman's wife passed away from this as well, and
• 16:18
  Speaker 4: so this is something that's kind of been percolating. But
• 16:21
  Speaker 4: how concerned should we be about the hunt of virus?
• 16:24
  Speaker 7: Yeah, and three people have perished on the boat, which
• 16:26
  Speaker 7: is obviously very sad. And I had with the current
• 16:30
  Speaker 7: knowledge that we have about these viruses, and there have
• 16:33
  Speaker 7: been other outbreaks before nineteen ninety three, there have been
• 16:36
  Speaker 7: transmissions to humans. It's a virus that doesn't transmit that easily.
• 16:41
  Speaker 7: It's not like COVID they just have to read someone's
• 16:43
  Speaker 7: breath in a restaurant and you catch it.
• 16:47
  Speaker 5: This is this requires.
• 16:48
  Speaker 7: Much closer contact, much higher duration of exposure, and quarantine
• 16:55
  Speaker 7: is the best way to silence it.
• 16:56
  Speaker 5: And but you need a functioning CDC that's.
• 17:01
  Speaker 7: On the ball finding people who have traveled back and
• 17:05
  Speaker 7: isolating them and finding their contacts and isolating them.
• 17:09
  Speaker 5: That's the best way to do it.
• 17:10
  Speaker 7: Don't forget, though, Scarlet viruses do have a nasty habit
• 17:14
  Speaker 7: of mutating, so we should always have that little thing
• 17:17
  Speaker 7: in the back of our mind that what we don't
• 17:19
  Speaker 7: want to happen. The more you allow it to transmit
• 17:22
  Speaker 7: to people, the more chancey gets.
• 17:24
  Speaker 4: Well, said Sam Fazelli. He is our director of Research
• 17:27
  Speaker 4: for Global Industries and senior pharmaceutols analysts for Bloomberg Intelligence,
• 17:30
  Speaker 4: joining us from London. A lot to cover here in
• 17:33
  Speaker 4: the world of biotech.
• 17:34
  Speaker 1: Always, always, This is the Bloomberg Intelligence podcast, available on Apple, Spotify,
• 17:41
  Speaker 1: and anywhere else you get your podcasts. Listen live each
• 17:44
  Speaker 1: weekday ten am to noon Eastern on Bloomberg dot com,
• 17:48
  Speaker 1: the iHeartRadio app, tune In, and the Bloomberg Business app.
• 17:52
  Speaker 1: You can also watch us live every weekday on YouTube
• 17:55
  Speaker 1: and always on the Bloomberg terminal.